EUCTR2014-002446-47-AT进行中（未招募）1 期
Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.
European Organization for Research and Treatment of Cancer (EORTC)0 个研究点目标入组 86 人开始时间: 2015年4月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 86
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •?Age 18 or older.
- •?Histological diagnosis of WHO grade II (chordoid meningioma, clear cell meningioma, atypical meningioma) or WHO grade III (papillary meningioma, rhabdoid meningioma, anaplastic/malignant meningioma) according to WHO 2007 classification.
- •?Radiologically documented progression of any existing tumor (growth > 25% in the last year) or appearance of new lesions (including intra- and extracranial manifestations).
- •?Measurable disease (10 x10 mm) on cranial MRI or CT thorax/abdomen no more than 2 weeks prior to randomization
- •?WHO performance status 0-2
- •?Adequate liver, renal and hematological function within 2 weeks prior to randomization, defined as:
- •?Neutrophils = 1.5 x 109/L, hemoglobin = 9 g/dL or hemoglobin = 5.6 mmol/L, platelets = 100 x 109/L
- •?Total Bilirubin = ULN, SGPT/ALT and SGOT/AST = 2.5 x ULN
- •?Alkaline phosphatase = 2.5 x ULN; if alkaline phosphatase > 2.5 ULN, hepatic isoenzymes 5-nucleotidase or gamma glutyamyltransferase (GGT) must be within the normal range
- •?Albumin = 30 g/L
- •?Serum creatinine = 1.5 x ULN
- •?Creatinine clearance > 30 ml/min as calculated by Cockcroft and Gault formula (see Appendix E)
- •?Creatine phosphokinase (CPK) = 2.5 x ULN
- •?Normal cardiac function (LVEF assessed by MUGA or ECHO within normal range of the institution), normal 12 lead ECG (without clinically significant abnormalities). The following unstable cardiac conditions are not allowed:
- •?Congestive heart failure
- •?Angina pectoris
- •?Myocardial infarction within 1 year before registration/randomization
- •?Uncontrolled arterial hypertension defined as blood pressure = 150/100 mm Hg despite optimal medical therapy
- •?Arrhythmias clinically significant
- •?Life expectancy of at least 9 weeks
- •Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior randomization (and again within 72 hours prior to to the first dose of study treatment). Patients of childbearing / reproductive potential should use adequate birth control measures, as defined below, during the study treatment period and for at least 3 months after the last study treatment. Men who are fertile must use effective contraception during treatment with trabectedin and for 5 months thereafter. Methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include:
- •? combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- •? intravaginal
- •? transdermal
- •? progestogen-only hormonal contraception associated with inhibition of ovulation:
- •? injectable
- •? implantable
- •? intrauterine device (IUD)
- •? intrauterine hormone-releasing system ( IUS)
- •? bilateral tubal occlusion
- •? vasectomised partner
- •? sexual abstinence
- •? Acceptable birth control methods that result in a failure rate of more
排除标准
- •?More option for local therapy (resection or radiotherapy) after maximal feasible surgery and radiotherapy.
- •?Prior systemic anti-neoplastic therapy for meningioma (patient may have received prior radionuclide therapy).
- •?History of any other invasive malignancy within the last 5 years (except adequately treated non-melanoma skin cancer, clinicaly localized and very low risk prostate cancer, and adequately treated cervical intraepithelial neoplasia).
- •?Serious illness or medical conditions, specifically: active infectious process; chronic active liver disease, including chronic hepatitis B, C or cirrhosis.
- •? Concomitant use of any other investigational agent, phenytoin, or vaccination to yellow fever.
- •? Known hypersensitivity or contraindication to trabectedin or any of the ingredients of the trabectedin solution for infusion
- •? Known MRI or CT, including contrast media, contraindications.
研究者
相似试验
进行中（未招募）
1 期
Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Recurrent high-grade meningiomaMedDRA version: 19.1 Level: PT Classification code 10027191 Term: Meningioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002446-47-DEEuropean Organization for Research and Treatment of Cancer (EORTC)86
进行中（未招募）
1 期
Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Recurrent high-grade meningiomaMedDRA version: 17.1 Level: PT Classification code 10027191 Term: Meningioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002446-47-ESEuropean Organization for Research and Treatment of Cancer (EORTC)86
进行中（未招募）
1 期
Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Recurrent high-grade meningiomaMedDRA version: 20.0 Level: PT Classification code 10027191 Term: Meningioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002446-47-NLEuropean Organization for Research and Treatment of Cancer (EORTC)86
已完成
2 期
Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.meningiomaNL-OMON44858European Organisation for Research in Treatment of Cancer (EORTC)3
进行中（未招募）
1 期
Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Recurrent high-grade meningiomaMedDRA version: 19.1Level: PTClassification code 10027191Term: MeningiomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002446-47-BEEuropean Organization for Research and Treatment of Cancer (EORTC)90